GlassScriptPhysician profile
Mariam M Rangwala
NPI 1881058410
$23,429.34
in general payments reported to CMS, 2019-2025
12 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22K · 2021: $249 · 2022: $316 · 2023: $364 · 2024: $413 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $10,000.00 | 2020 | |
| Abbott Laboratories | $6,934.17 | 2020-2025 | Infinity |
| Boston Scientific Corporation | $5,249.13 | 2020-2021 | |
| Abbvie INC. | $896.85 | 2021-2025 | |
| Allergan, INC. | $104.05 | 2020-2021 | |
| Pfizer INC. | $61.15 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $49.30 | 2022-2023 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $42.01 | 2022-2023 | Rytary |
| Kyowa Kirin, INC. | $28.80 | 2022 | |
| Eisai INC. | $22.61 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.65 | 2022 | |
| Amgen INC. | $20.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Rangwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.